Key Developments: Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

84.60EUR
24 Oct 2014
Price Change (% chg)

€-0.30 (-0.35%)
Prev Close
€84.90
Open
€84.60
Day's High
€84.89
Day's Low
€84.02
Volume
2,561,457
Avg. Vol
3,148,961
52-wk High
€89.95
52-wk Low
€68.29

Search Stocks

Latest Key Developments (Source: Significant Developments)

Ferring Pharmaceuticals to acquire marketing rights for DDAVP (desmopressin) product portfolio from Sanofi SA
Wednesday, 22 Oct 2014 09:00am EDT 

Ferring Pharmaceuticals:Says company has acquired DDAVP (desmopressin acetate) from Sanofi.DDAVP is available in tablets, nasal spray rhinal tube and injection.  Full Article

US FDA accepts for review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
Monday, 20 Oct 2014 08:00am EDT 

Merck & Co Inc and Sanofi Pasteur:Says the Biologics License Application (BLA) filed for the companies` investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB1, has been accepted for review by the U.S. Food and Drug Administration (FDA).Says data from a Phase III study for the investigational pediatric hexavalent vaccine were recently presented at IDWeek in Philadelphia.Says this phase III study, a randomized, open-label, active-comparator controlled clinical trial with more than 1,400 infants at multiple centers across the United States, evaluated the safety and immunogenicity of the investigational pediatric hexavalent vaccine versus licensed comparator vaccines.Says the partnership between Merck and Sanofi Pasteur draws upon both companies' experience in the development, manufacturing and marketing of individual and combination vaccines.Sanofi Pasteur, is the vaccines division of Sanofi.  Full Article

Sanofi and Regeneron announce start of Phase 3 study of dupilumab in patients with atopic dermatitis
Monday, 20 Oct 2014 01:00am EDT 

Sanofi SA:Announces together with Regeneron Pharmaceuticals that first patients have been dosed in Phase 3 clinical study of dupilumab.Dupilumab is investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.Trial is to enroll about 700 adult patients.LIBERTY AD Phase 3 clinical program to consist of at least five trials of patients with moderate-to-severe AD at sites worldwide.  Full Article

Sanofi Pasteur and Immune Design collaborate on vaccine to treat Herpes Simplex Virus
Thursday, 16 Oct 2014 01:00am EDT 

Sanofi SA:Says Sanofi Pasteur and Immune Design collaborate on vaccine to treat Herpes Simplex Virus.Says Sanofi Pasteur will contribute HSV-529, clinical-stage replication-defective HSV vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine product candidate.Says collaboration will explore potential of various combinations of agents, including Immune Design's GLAASTM platform, with goal to select potential immune therapy for patients.Says two companies will develop products jointly through Phase II clinical trials, at which point Sanofi Pasteur intends to continue development of most promising candidate and be responsible for commercialization.Says Sanofi Pasteur will bear costs of all preclinical and clinical development, with Immune Design providing specific formulation of GLA from the GLAAS platform at its cost through Phase II studies.Says Immune Design will be eligible to receive future milestone and royalty payments on any product developed from collaboration.Says other financial terms of agreement have not been disclosed.  Full Article

Selecta, JDRF and Sanofi extend collaboration to develop a synthetic vaccine particle Immunotherapy for Type 1 Diabetes
Wednesday, 15 Oct 2014 07:25am EDT 

Selecta Biosciences, Inc., and JDRF:Says that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes.Says this collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas.Says JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic.  Full Article

Sanofi Pasteur announces start of phase III trial of candidate rotavirus vaccine
Tuesday, 14 Oct 2014 01:01am EDT 

Sanofi SA:Sanofi Pasteur announces start of clinical phase III trial in India for its candidate rotavirus vaccine.Candidate rotavirus vaccine is developed and manufactured by subsidiary Shantha Biotechnics in Hyderabad, India.  Full Article

Apollo Hospitals Enterprise Ltd and Sanofi SA announce collaboration
Tuesday, 30 Sep 2014 07:15am EDT 

Apollo Hospitals Enterprise Ltd And Sanofi SA:Says their decision to collaborate on the expansion of Apollo Sugar Clinics, which integrated diabetes care programs.Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes.  Full Article

Regeneron Pharmaceuticals Inc and Sanofi SA announce positive phase 2 top-line dupilumab results in patients with chronic sinusitis with nasal polyps
Tuesday, 30 Sep 2014 01:00am EDT 

Regeneron Pharmaceuticals Inc and Sanofi SA:Announce that phase 2a proof-of-concept study of dupilumab, investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.These data suggest potential of dupilumab for use in treatment of another allergic inflammatory condition.In the study, dupilumab resulted in statistically-significant improvement in size of nasal polyps, as measured by endoscopic Nasal Polyp Score (NPS), primary endpoint of study.Statistically significant improvements in all secondary efficacy endpoints were also observed, including objective measures of sinusitis by CT scan, nasal air flow, and patient-reported symptoms (sense of smell, congestion, postnasal drip, runny nose and sleep disturbance).In pre-specified exploratory analysis, dupilumab-treated patients who also had asthma demonstrated significant improvements in asthma control.Safety profile was consistent with previous studies.Most common AEs with dupilumab were injection site reactions, nasopharyngitis, oropharyngeal pain, epistaxis, headache and dizziness.  Full Article

Genfit signs extension to shared research agreement with Sanofi with increased milestone payments
Tuesday, 23 Sep 2014 02:30am EDT 

Genfit SA:Signs extension to shared research agreement with Sanofi until May 2015.Obtains as part of renewal increase in milestone payments linked to different clinical development phases of drug candidates.  Full Article

Sanofi and MyoKardia announce collaboration to develop targeted therapies for genetic heart disease
Wednesday, 17 Sep 2014 01:00am EDT 

Sanofi SA:Announces a worldwide collaboration with MyoKardia Inc to discover and develop targeted therapeutics for heritable heart diseases known as cardiomyopathies.The collaboration encompasses three MyoKardia programs.Two of these programs are focused on hypertrophic cardiomyopathy (HCM) and the other is focused on dilated cardiomyopathy (DCM).The collaboration provides up to $200 million in equity investments, milestone payments and research and development services through 2018, of which $45 million has already been received in an upfront licensing fee and an initial equity investment.Sanofi and MyoKardia will equally share development costs on the HCM programs following initial demonstration of efficacy in patients, with Sanofi fully covering the development costs of the DCM program.  Full Article

Actavis, Sanofi among bidders for Omega Pharma: Bloomberg

- Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV [COUCKO.UL], Bloomberg reported, citing people familiar with the matter.

Search Stocks